文献速递临床试验与 GCP

淋巴清扫范围——D2清扫对比完整结肠系膜切除的腹腔镜右半结肠癌根治术(RELARC)试验:随机对照试验研究方案

The Radical Extent of lymphadenectomy - D2 dissection versus complete mesocolic excision of LAparoscopic Right Colectomy for right-sided colon cancer (RELARC) trial: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2016-12-08

RELARC试验为前瞻性多中心随机对照试验,计划纳入1072例右侧结肠癌患者,随机分入CME组或D2清扫组,比较腹腔镜右半结肠切除术中两种淋巴清扫范围的肿瘤学结局与手术安全性。主要终点为3年无病生存率,次要终点包括3年总生存率、术后并发症率、围手术期死亡率和中央淋巴结(第3站)阳性率。

要点

  • RELARC试验比较腹腔镜右半结肠癌根治术中CME与D2清扫的肿瘤学结局与手术安全性。
  • 计划纳入1072例右侧结肠癌患者,随机分入CME组或D2清扫组。
  • 主要终点为3年无病生存率,次要终点包括3年总生存率、术后并发症率、围手术期死亡率和中央淋巴结阳性率。

核心结论

  • RELARC试验将为腹腔镜右半结肠切除术中淋巴清扫的最佳范围提供肿瘤学结局与手术安全性方面的证据。

研究设计与样本

  • RELARC研究为前瞻性、多中心、随机对照试验,计划纳入1072例符合条件的右侧结肠癌患者,随机分配至CME组或D2清扫组。
  • 纳入标准为盲肠至横结肠右三分之一处的局部进展期结肠癌,临床分期为T2-4aN0M0或TanyN+M0。

主要发现

  • 主要终点为3年无病生存率。
  • 次要终点包括3年总生存率、术后并发症率、围手术期死亡率和中央淋巴结(第3站)阳性率。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The extent of lymphadenectomy during laparoscopic right colectomy can affect the oncological outcome and the safety of surgery. The principle of complete mesocolic excision (CME) has been gradually accepted and increasingly applied by colorectal surgeons. The aim of this study is to investigate whether extended lymphadenectomy (CME) in laparoscopic colectomy could improve the oncological outcomes of patients with right-sided colon cancers, compared with D2 lymphadenectomy. METHODS/DESIGN: The Radical Extent of lympadenectomy: D2 dissection versus complete mesocolic excision of LAparoscopic Right Colectomy for right-sided colon cancer (RELARC) study is a prospective, multicenter, randomized controlled trial in which 1072 eligible patients with right-sided colon cancers will be randomly assigned to the CME group or the D2 dissection group during laparoscopic right colectomy. Inclusion criteria are locally advanced colon cancers situated from the cecum to the right third of the transverse colon and clinically staged as T2-4aN0M0 or TanyN + M0. The primary endpoint of this trial is 3-year disease-free survival. Secondary endpoints include 3-year overall survival, postoperative complication rates, perioperative mortality rates, and rates of positive central lymph nodes (the station 3 nodes). DISCUSSION: The RELARC trial is a prospective, multicenter, randomized controlled trial that will provide evidence on the optimal extent of lymphadenectomy during laparoscopic right colectomy in terms of better oncological outcome and operation safety. TRIAL REGISTRATION: ClinicalTrials.gov: NCT02619942 . Registered on 29 November 2015.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Lu JY, Xu L, Xue HD, et al. The Radical Extent of lymphadenectomy - D2 dissection versus complete mesocolic excision of LAparoscopic Right Colectomy for right-sided colon cancer (RELARC) trial: study protocol for a randomized controlled trial. Trials. 2016. PMID: 27931247

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。